Document is current
Any future updates will be listed below
-
Authors
Hayes, Daniel F.
Sauerbrei, Willi
McShane, Lisa M.
- License Information
-
More Information
Article History
Received: 27 September 2022
Revised: 17 October 2022
Accepted: 21 October 2022
First Online: 7 December 2022
Competing interests
: DFH has no conflicts specifically related to this study. DFH reports support unrelated to this study but provided to his institution in the last 24 months during conduct and analysis of this study from Astra Zeneca, Menarini Silicon Biosystems, Merrimack Pharmaceuticals, and Pfizer. DFH reports personal income related to consulting or advisory board activities from BioVeca, Cellworks, Cepheid, EPIC Sciences, EXACT Sciences, Freenome, Guardant, L-Nutra, Macrogenics, Oncocyte, Predictus BioSciences, Tempus, Turnstone Biologics, and Xilis. The University of Michigan holds a patent for which DFH is the named investigator and which is licensed to Menarini Silicon Biosystems from whom UM and DFH receive annual royalties. DFH reports personally held stock options from InBiomotion. LMM declares no conflicts. WS declares no conflicts.
